Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Pharmacokinetics and Toxicology (PK/Tox) Studies

Active
SBIR / STTR

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

Department of Health and Human Services → NIHView Agency

NAICS

541611 - Administrative Management and General Management Consulting ServicesView NAICS

Place of Performance

Not specified

Set-Aside

SBA

Documents

This scope was carved out of 75N98026R00109.

The full solicitation package (3 documents), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Development of therapeutic or preventative technologies for treatment or prevention of Pediatric Cancers and/or Rare Cancers.

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment of Health and Human Services → NIH
ContactsNo contacts available
OfficeN/A
Organization / Agency
Department of Health and Human Services → NIH
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Evaluate ADME properties and preliminary toxicity of lead candidates in rodent models using plasma sampling and LC-MS/MS analysis.

Similar Contracts

Same NAICS industry code

More opportunities from Department of Health and Human Services → NIH

Same awarding agency

NAICS: 541715
SBIR / STTR
Development of devices, diagnostic technologies, or digital health tools for treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers.
Solicitation # 75N98026R00109
The National Institutes of Health, through the National Cancer Institute, is soliciting proposals for the SBIR Innovative Concept Phase I Award Program under solicitation 75N98026R00109. This program targets the development of high-risk, disruptive technologies, including therapies, devices, diagnostic tools, and digital health solutions specifically for pediatric and rare cancers. Defined as malignancies with a U.S. prevalence of fewer than 200,000 individuals, these cancers represent a significant unmet medical need. The primary goal is for small businesses to demonstrate proof-of-concept and generate de-risking technical data. While preliminary data is not required, proposals must be based on a sound scientific premise. The program also provides business and commercialization resources, including entrepreneurship training, to help offerors refine their business models. Eligible applicants must be small business concerns with fewer than 500 employees. The estimated contract value is between 300,000 and 306,500 dollars, which includes a base budget of 300,000 dollars and an optional 6,500 dollars for Technical and Business Assistance. Awards are determined via a trade-off process, prioritizing potential for innovation and impact, which accounts for 50 percent of the evaluation weight, followed by scientific rationale, commercialization potential, and personnel qualifications. Proposals must be submitted via the eCPS portal by September 21, 2026. Strict compliance is required regarding foreign affiliation disclosures and the use of NIH-formatted biosketches for key personnel. All research and development work must be performed within the United States.
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

POSTED

about 2 months ago

DEADLINE

in 20 days
View Details